219 related articles for article (PubMed ID: 20352409)
21. FRAX-derived intervention and assessment thresholds for osteoporosis in ten Middle Eastern countries.
Naseri A; Bakhshayeshkaram M; Salehi S; Heydari ST; Dabbaghmanesh MH; Dabbaghmanesh MM
Arch Osteoporos; 2024 May; 19(1):41. PubMed ID: 38780743
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective.
Borgström F; Ström O; Kleman M; McCloskey E; Johansson H; Odén A; Kanis JA
Osteoporos Int; 2011 Mar; 22(3):955-65. PubMed ID: 20532482
[TBL] [Abstract][Full Text] [Related]
23. Osteoporosis treatment in Austria-assessment of FRAX-based intervention thresholds for high and very high fracture risk.
Dimai HP; Johansson H; Harvey NC; Lorentzon M; Liu E; Vandenput L; Fahrleitner-Pammer A; Pietschmann P; Muschitz C; McCloskey EV; Kanis JA
Arch Osteoporos; 2022 Nov; 17(1):141. PubMed ID: 36357621
[TBL] [Abstract][Full Text] [Related]
24. The application of FRAX in Saudi Arabia.
Al-Daghri NM; Sabico S; Al-Saleh Y; Sulimani R; Aljohani NJ; Sheshah E; Alodhayani A; Harvey NC; Liu E; Lorentzon M; McCloskey EV; Vandenput L; Johansson H; Kanis JA
Arch Osteoporos; 2021 Nov; 16(1):166. PubMed ID: 34739604
[TBL] [Abstract][Full Text] [Related]
25. FRAX and the assessment of fracture probability in men and women from the UK.
Kanis JA; Johnell O; Oden A; Johansson H; McCloskey E
Osteoporos Int; 2008 Apr; 19(4):385-97. PubMed ID: 18292978
[TBL] [Abstract][Full Text] [Related]
26. The application of FRAX® to determine intervention thresholds in osteoporosis treatment in Poland.
Badurski JE; Kanis JA; Johansson H; Dobreńko A; Nowak NA; Daniluk S; Jezienicka E
Pol Arch Med Wewn; 2011 May; 121(5):148-55. PubMed ID: 21610662
[TBL] [Abstract][Full Text] [Related]
27. The role of bone mineral density in therapeutic decision-making using the Fracture Risk Assessment Tool (FRAX): a sub-study of the Taiwan OsteoPorosis Survey (TOPS).
Chen JF; Yu SF; Hsu CY; Chiu WC; Wu CH; Lai HM; Chen YC; Su YJ; Chen JF; Cheng TT
Arch Osteoporos; 2019 Oct; 14(1):101. PubMed ID: 31650396
[TBL] [Abstract][Full Text] [Related]
28. Implications of expanding indications for drug treatment to prevent fracture in older men in United States: cross sectional and longitudinal analysis of prospective cohort study.
Ensrud KE; Taylor BC; Peters KW; Gourlay ML; Donaldson MG; Leslie WD; Blackwell TL; Fink HA; Orwoll ES; Schousboe J;
BMJ; 2014 Jul; 349():g4120. PubMed ID: 24994809
[TBL] [Abstract][Full Text] [Related]
29. Incidence of hip fracture in Brazil and the development of a FRAX model.
Zerbini CA; Szejnfeld VL; Abergaria BH; McCloskey EV; Johansson H; Kanis JA
Arch Osteoporos; 2015; 10():224. PubMed ID: 26303038
[TBL] [Abstract][Full Text] [Related]
30. Sri Lankan FRAX model and country-specific intervention thresholds.
Lekamwasam S
Arch Osteoporos; 2013; 8():148. PubMed ID: 23975235
[TBL] [Abstract][Full Text] [Related]
31. Guidance for the adjustment of FRAX according to the dose of glucocorticoids.
Kanis JA; Johansson H; Oden A; McCloskey EV
Osteoporos Int; 2011 Mar; 22(3):809-16. PubMed ID: 21229233
[TBL] [Abstract][Full Text] [Related]
32. The impact of a FRAX-based intervention threshold in Turkey: the FRAX-TURK study.
Tuzun S; Eskiyurt N; Akarirmak U; Saridogan M; Johansson H; McCloskey E; Kanis JA;
Arch Osteoporos; 2012; 7():229-35. PubMed ID: 23060308
[TBL] [Abstract][Full Text] [Related]
33. FRAX-based Estimates of 10-year Probability of Hip and Major Osteoporotic Fracture Among Adults Aged 40 and Over: United States, 2013 and 2014.
Looker AC; Sarafrazi Isfahani N; Fan B; Shepherd JA
Natl Health Stat Report; 2017 Mar; (103):1-16. PubMed ID: 28459415
[TBL] [Abstract][Full Text] [Related]
34. Cost-effective osteoporosis treatment thresholds in Greece.
Makras P; Athanasakis K; Boubouchairopoulou N; Rizou S; Anastasilakis AD; Kyriopoulos J; Lyritis GP
Osteoporos Int; 2015 Jul; 26(7):1949-57. PubMed ID: 25740208
[TBL] [Abstract][Full Text] [Related]
35. Osteoporosis treatment considerations based upon fracture history, fracture risk assessment, vertebral fracture assessment, and bone density in Canada.
Leslie WD; Lix LM; Binkley N
Arch Osteoporos; 2020 Jun; 15(1):93. PubMed ID: 32577922
[TBL] [Abstract][Full Text] [Related]
36. Use of age-dependent FRAX-based intervention thresholds for Singapore.
Kanis JA; Chandran M; Chionh SB; Ganeson G; Harvey NC; Koh WP; Kwok T; Lau TC; Liu E; Lorentzon M; McCloskey EV; Tan KB; Vandenput L; Johansson H
Arch Osteoporos; 2020 Jul; 15(1):104. PubMed ID: 32700118
[TBL] [Abstract][Full Text] [Related]
37. The FRAX-based Lebanese osteoporosis treatment guidelines: rationale for a hybrid model.
Chakhtoura M; Leslie WD; McClung M; Cheung AM; Fuleihan GE
Osteoporos Int; 2017 Jan; 28(1):127-137. PubMed ID: 27650643
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX criteria.
Bruyère O; Fossi M; Zegels B; Leonori L; Hiligsmann M; Neuprez A; Reginster JY
Rheumatol Int; 2013 Apr; 33(4):973-8. PubMed ID: 22842952
[TBL] [Abstract][Full Text] [Related]
39. Epidemiology of hip fracture and the development of FRAX in Ukraine.
Povoroznyuk VV; Grygorieva NV; Kanis JA; Ev M; Johansson H; Harvey NC; Korzh MO; Strafun SS; Vaida VM; Klymovytsky FV; Vlasenko RO; Forosenko VS
Arch Osteoporos; 2017 Dec; 12(1):53. PubMed ID: 28567714
[TBL] [Abstract][Full Text] [Related]
40. Fracture Risk Indices From DXA-Based Finite Element Analysis Predict Incident Fractures Independently From FRAX: The Manitoba BMD Registry.
Leslie WD; Luo Y; Yang S; Goertzen AL; Ahmed S; Delubac I; Lix LM
J Clin Densitom; 2019; 22(3):338-345. PubMed ID: 30852033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
